Core Viewpoint - The company Hotgen Biotech (688068.SH) has announced that its main business involves the research, production, and sales of in vitro diagnostic reagents and related instruments, while its biopharmaceutical innovation and early cancer screening businesses are independently operated by joint ventures [1] Group 1 - The main business of Hotgen Biotech is focused on in vitro diagnostic reagents and related instruments [1] - The biopharmaceutical innovation and early cancer screening businesses are managed by joint ventures including ShunJing Pharmaceutical, YaoJing Genetics, ZhiYuan Biotech, and AoRui Biotech [1] - The related businesses are characterized by high research and development investment and significant research risks [1]

5月24日，以"创新驱动发展科技引领未来"为主题的2025年青岛市科技活动周在中国科学院青岛能源所 新源路园区正式启动。启动仪式上，山东言鼎控股集团总经理肖乐义教授领衔的"细胞液体病理活检技 术研究与产业化应用"项目团队凭借在肿瘤早筛领域的突破性成果，成功入选青岛市产业领军人才（团 队）。言鼎集团董事长刘元柱代表团队上台领奖，市委常委、副市长王波为其颁发荣誉证书。 在刘元柱董事长战略布局下，言鼎集团构建了"引育并举"的人才培养体系。该项目团队整合生物医学工 程、微流控技术、多模态医疗大数据等领域的专业力量，形成跨学科创新联合体。集团已与青岛大学、 中国科学院理化技术研究所、郑州大学第一附属医院等高校、科研院所及医疗机构建立合作，共建山东 省公共卫生临床中心联合实验室、青医附院-青岛大学生命科学学院联合实验室、安徽亳州高新科创医 药产业技术研究院实验室、国家肿瘤细胞公共研发服务平台河南分中心、平台新乡医学院第一附属医院 肿瘤医院分中心等多个科研平台，并在北京、珠海、辽宁、安徽、聊城设立分支机构。 肖乐义先生作为技术带头人，深耕基因与微流控芯片领域数十载，主持国家级科研项目4项，累计发表 论文48篇，获授权专利数 ...

Core Viewpoint - The company reported a significant decline in revenue and net profit for the reporting period, marking its first annual loss since listing, primarily due to industry policy adjustments and market demand changes affecting its molecular diagnostic products and medical testing services [9][10][11]. Company Overview - The company is a leading provider of integrated molecular diagnostic products and services in China, focusing on three main business segments: molecular diagnostic products, medical testing services, and healthcare services [5][7]. - It has developed a wide range of products for tumor screening, infectious and genetic disease testing, and maternal and child health management, which are widely used in clinical diagnosis and public health [5][6]. Financial Performance - The company achieved operating revenue of 815.53 million yuan, a year-on-year decrease of 26.16%, with a net profit attributable to shareholders of -654.88 million yuan, a decline of 566.20% [9][10]. - The decline in revenue was attributed to price reductions in molecular diagnostic products due to policy changes and a decrease in demand for medical testing services, leading to operational losses in these segments [10][11]. Business Development - The company has been actively promoting its HPV testing products, responding to the national initiative to eliminate cervical cancer, and has conducted numerous public awareness campaigns [12][13]. - It has established a network of 31 third-party medical laboratories across China, focusing on high-end testing technologies and expanding its service offerings [7][8]. Product Innovation - The company has invested over 860 million yuan in research and development since its inception, with a focus on enhancing its molecular diagnostic product line and obtaining various medical device certifications [18][19]. - New product developments include a range of genetic testing kits and personalized medicine solutions, which have seen increased usage and sales [16][20]. Strategic Initiatives - The company is implementing the "Kepu Kanghe Medical Testing 5.0" strategy, integrating precision medicine and health management to provide comprehensive health services [8][22]. - It is also focusing on international expansion, having obtained multiple certifications and patents in various countries, and is actively participating in international exhibitions to showcase its products [26][27]. Operational Efficiency - The company is taking measures to reduce costs and improve operational efficiency in its medical laboratory segment, including optimizing laboratory operations and consolidating facilities [28][31]. - It has also adjusted its workforce structure to enhance productivity, with a significant reduction in personnel costs planned for the upcoming year [33][34].

为传播科学防癌治癌理念，增强公众的防癌抗癌意识，"人民好医生"客户端推出专场系列科普直播。 李乐平，山东省立医院普外科主任、胃肠外科主任，泰山学者特聘专家，二级教授，博士生导师，国务院特贴专家,山东省消化肿瘤转化医学重点工 程实验室主任，山东省消化肿瘤基础与临床重点高校实验室主任，国家卫健委能力提升与继续教育外科学专业委员会副主任委员，国家胃癌质控专家委员 会副主任委员，国家结直肠质控专家委员会副主任委员，中华医学会外科学分会全国委员，山东省医学会外科专业委员会第六届主任委员、现候任主任委 员等。 如何收看直播： 一、下载人民好医生App，点击"名医直播"进入栏目进行收看。 谈及肿瘤疾病，难免让人心生恐慌，然而一些高发病率的恶性肿瘤却没有因为人们忌讳而悄然退去。但近年来，胃癌、结直肠癌的发生成为威胁公众 健康的隐患之一。那么，如何正确认识胃肠肿瘤？如何及早发现和科学治疗？ 4月29日14:00至15:00，山东省立医院普外科主任、胃肠外科主任李乐平做客"人民好医生"客户端直播间，就胃肠肿瘤早筛与诊疗的相关问题与网友们 进行讲解与交流。 嘉宾简介： 更多贴心易懂的健康科普，三甲名医直播互动，请关注人民好医生AP ...